Aerospace & Defense · Founded 1993 · www.zentechnologies.com · BSE 533339 · NSE ZEN TECH · ISIN INE251B01027
No Notes Added Yet
Business
Zen Technologies Ltd. is an Indian company that designs, develops, and manufactures advanced combat training solutions and anti-drone systems. Its core business involves providing high-fidelity simulation products for military, paramilitary, and police forces, enabling realistic training scenarios for various weapon systems, vehicles, and combat situations. More recently, the company has diversified into developing and deploying integrated counter-drone systems (ZADS) to detect, classify, track, and neutralize hostile drones. Zen Technologies makes money primarily through the sale of these sophisticated systems and associated long-term maintenance, spares, and upgrade contracts.
Revenue Mix
Zen Technologies' revenue streams primarily stem from two broad categories:
Training Simulators: This segment includes a wide range of virtual, live-fire, and constructive simulators for small arms, tank, artillery, air defense, driving, and remotely operated vehicle operations, catering to various branches of the armed forces and internal security agencies.
Anti-Drone Systems: This segment focuses on providing comprehensive solutions for counter-unmanned aerial systems (C-UAS), encompassing detection, identification, tracking, and neutralization capabilities to protect critical assets and infrastructure from drone threats.
Specific revenue contribution percentages for each segment are typically not disclosed granularly but simulators have historically been the dominant segment, with anti-drone systems gaining significant traction more recently.
Industry
Zen Technologies operates within the Indian Defence sector, specifically in the niche of defense simulation and C-UAS technology. The industry is highly regulated, primarily driven by government procurement, and undergoing a significant push for indigenization ("Make in India"). Zen Technologies is positioned as a leading indigenous player in India for advanced defense simulators, often being a preferred or sole Indian vendor for specific complex systems. In the burgeoning anti-drone segment, it is one of the frontrunners offering integrated solutions, competing with both domestic and international players (often through collaborations). Its long-standing relationships with the Indian armed forces provide a strong market foothold.
MOAT
Indigenous R&D and Technology: Zen Technologies has a strong in-house R&D capability, enabling it to develop and customize complex simulation software and hardware specifically tailored to the Indian military's evolving requirements. This reduces reliance on foreign technology and creates proprietary intellectual property.
Established Relationships: Decades of experience and successful project execution have built deep trust and credibility with the Indian armed forces, paramilitary forces, and police.
Niche Expertise: Specialization in high-tech simulation and anti-drone systems allows for focused product development and innovation in critical defense domains.
High Switching Costs: Once a simulation system is integrated into a defense force's training ecosystem, switching to a new vendor can involve significant costs related to retraining personnel, system compatibility, and potential disruption to ongoing training programs.
Growth Drivers
"Make in India" and Indigenization Push: The Indian government's strong emphasis on domestic procurement and reducing import dependence significantly favors Indian defense manufacturers like Zen Technologies.
Modernization of Armed Forces: Continuous upgrade and modernization programs of the Indian Army, Navy, and Air Force necessitate advanced training systems and cutting-edge counter-threat technologies.
Rising Drone Threats: The increasing proliferation and sophistication of drones globally and regionally drive substantial demand for robust anti-drone systems for critical infrastructure and border security.
Increasing Defence Budget: Consistent allocation of a substantial portion of the national budget towards defense, particularly capital outlay for new equipment and technology.
Export Potential: Growing interest from friendly foreign countries in acquiring proven, cost-effective Indian defense technologies presents an opportunity for international expansion.
Risks
Dependence on Government Orders: Revenue is heavily reliant on procurement cycles and tenders from the Indian Ministry of Defence and other government agencies, making it susceptible to policy changes, budget cuts, and lumpy order flows.
Long Sales Cycles: Defence procurement involves prolonged negotiation, tender, and approval processes, leading to extended revenue recognition timelines and potential project delays.
Intense Competition: The entry of more domestic private players and strategic partnerships between international and Indian companies can intensify competition in both simulation and anti-drone markets.
Technological Obsolescence: The rapid pace of technological change in defense necessitates continuous and substantial R&D investments to remain competitive and relevant.
Execution Risks: Delays in project delivery, cost overruns, or failure to meet stringent military specifications can impact profitability and reputation.
Management & Ownership
The company is primarily promoter-driven, with Ashok Atluri (Chairman & Managing Director) and Ravi Kumar Atluri (Joint Managing Director) having long-standing involvement since its inception. The promoter group typically holds a significant equity stake, indicating strong alignment with shareholder interests. The management has demonstrated a consistent focus on indigenous R&D and securing defence contracts.
Outlook
Zen Technologies is well-positioned to benefit from India's renewed focus on defense indigenization and increasing defense spending, particularly in the critical areas of advanced training and counter-drone systems. A healthy order book and demonstrated technological capabilities in niche segments are strong positives. However, its business remains inherently dependent on lumpy government procurement cycles and intense competition, necessitating efficient project execution and continuous innovation. The company's ability to scale up production and successfully deliver on its growing order book, alongside securing new export opportunities, will be crucial determinants of its future performance, while potential delays in tender awards or project completion could temper growth expectations.
Price goes above X
Price falls below X
PE goes above X
PE falls below X
| #(Fig in Cr.) | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Net Sales | 141 | 255 | 242 | 152 | 325 | 158 | 174 | 178 | 178 | 142 |
| Other Income | 3 | 3 | 8 | 22 | 25 | 22 | 25 | 16 | 23 | 19 |
| Total Income | 144 | 258 | 250 | 174 | 350 | 180 | 199 | 193 | 201 | 161 |
| Total Expenditure | 91 | 143 | 162 | 108 | 187 | 94 | 109 | 111 | 127 | 103 |
| Operating Profit | 53 | 114 | 88 | 66 | 163 | 86 | 90 | 82 | 74 | 58 |
| Interest | 1 | 1 | 2 | 3 | 4 | 3 | 2 | 3 | 2 | 1 |
| Depreciation | 3 | 3 | 4 | 4 | 5 | 6 | 6 | 6 | 6 | 8 |
| Exceptional Income / Expenses | 2 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | -3 |
| Profit Before Tax | 52 | 110 | 82 | 59 | 154 | 77 | 83 | 73 | 66 | 46 |
| Provision for Tax | 14 | 31 | 19 | 17 | 40 | 23 | 21 | 17 | 17 | 13 |
| Profit After Tax | 38 | 79 | 63 | 43 | 114 | 54 | 62 | 56 | 49 | 32 |
| Adjustments | -3 | -3 | -1 | -3 | -13 | -6 | -3 | -1 | -17 | 2 |
| Profit After Adjustments | 35 | 77 | 63 | 40 | 101 | 48 | 59 | 55 | 32 | 34 |
| Adjusted Earnings Per Share | 4.2 | 9.1 | 6.9 | 4.4 | 11.2 | 5.3 | 6.6 | 6.1 | 3.5 | 3.8 |
| #(Fig in Cr.) | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net Sales | 79 | 53 | 62 | 92 | 149 | 55 | 70 | 219 | 440 | 974 | 688 | 672 |
| Other Income | 6 | 6 | 4 | 3 | 2 | 3 | 5 | 7 | 15 | 58 | 85 | 83 |
| Total Income | 84 | 58 | 65 | 95 | 151 | 58 | 75 | 226 | 455 | 1032 | 773 | 754 |
| Total Expenditure | 58 | 49 | 50 | 76 | 87 | 47 | 65 | 146 | 259 | 591 | 440 | 450 |
| Operating Profit | 26 | 10 | 15 | 20 | 65 | 10 | 10 | 80 | 196 | 441 | 333 | 304 |
| Interest | 2 | 2 | 2 | 5 | 3 | 1 | 2 | 4 | 2 | 19 | 10 | 8 |
| Depreciation | 4 | 4 | 4 | 4 | 5 | 5 | 5 | 6 | 10 | 15 | 24 | 26 |
| Exceptional Income / Expenses | 0 | 0 | 0 | 0 | 0 | 0 | -0 | 2 | 2 | 0 | 1 | -2 |
| Profit Before Tax | 20 | 3 | 9 | 11 | 57 | 4 | 3 | 72 | 186 | 406 | 297 | 268 |
| Provision for Tax | 4 | 1 | 2 | -2 | -2 | 2 | 1 | 22 | 57 | 107 | 79 | 68 |
| Profit After Tax | 16 | 2 | 7 | 13 | 59 | 3 | 3 | 50 | 130 | 299 | 218 | 199 |
| Adjustments | 0 | 0 | 0 | 0 | 0 | 0 | -1 | -7 | -2 | -19 | -24 | -19 |
| Profit After Adjustments | 16 | 2 | 7 | 13 | 59 | 3 | 2 | 43 | 128 | 280 | 193 | 180 |
| Adjusted Earnings Per Share | 2 | 0.3 | 0.9 | 1.7 | 7.6 | 0.4 | 0.2 | 5.4 | 15.2 | 31 | 21.4 | 20 |
| # | 1 Year | 3 Year | 5 Year | 10 Year |
|---|---|---|---|---|
| Sales CAGR | -29% | 46% | 66% | 24% |
| Operating Profit CAGR | -24% | 61% | 102% | 29% |
| PAT CAGR | -27% | 63% | 136% | 30% |
| # | 1 Year | 3 Year | 5 Year | 10 Year |
|---|---|---|---|---|
| Share Price CAGR | 11% | 31% | 51% | 36% |
| ROE Average | 12% | 25% | 18% | 15% |
| ROCE Average | 17% | 35% | 26% | 19% |
| #(Fig in Cr.) | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Shareholder's Funds | 111 | 112 | 120 | 135 | 191 | 204 | 283 | 316 | 449 | 1701 | 1889 |
| Minority's Interest | 0 | 0 | 0 | 0 | 7 | 6 | 7 | 14 | 18 | 35 | 60 |
| Borrowings | 4 | 8 | 6 | 9 | 1 | 1 | 4 | 0 | 0 | 40 | 1 |
| Other Non-Current Liabilities | 1 | 1 | 1 | -7 | -19 | -19 | -17 | -11 | 14 | 24 | 27 |
| Total Current Liabilities | 62 | 46 | 20 | 73 | 13 | 10 | 72 | 140 | 270 | 244 | 175 |
| Total Liabilities | 177 | 167 | 146 | 210 | 194 | 203 | 349 | 460 | 751 | 2045 | 2153 |
| Fixed Assets | 47 | 44 | 45 | 63 | 73 | 70 | 67 | 75 | 93 | 208 | 239 |
| Other Non-Current Assets | 7 | 22 | 24 | 24 | 5 | 3 | 6 | 52 | 39 | 32 | 360 |
| Total Current Assets | 123 | 101 | 78 | 123 | 116 | 130 | 275 | 332 | 618 | 1804 | 1554 |
| Total Assets | 177 | 167 | 146 | 210 | 194 | 203 | 349 | 460 | 751 | 2045 | 2153 |
| #(Fig in Cr.) | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Opening Cash & Cash Equivalents | 42 | 38 | 68 | 10 | -22 | 16 | 21 | 21 | 112 | 37 | 74 |
| Cash Flow from Operating Activities | -20 | 43 | 2 | -49 | 62 | 6 | -44 | 116 | 13 | 31 | 245 |
| Cash Flow from Investing Activities | -4 | -9 | -4 | 13 | -12 | -10 | -44 | -4 | -85 | -1000 | -161 |
| Cash Flow from Financing Activities | 20 | -3 | -32 | 5 | -12 | 9 | 88 | -22 | -3 | 1007 | -78 |
| Net Cash Inflow / Outflow | -4 | 30 | -34 | -32 | 38 | 5 | 0 | 91 | -75 | 37 | 5 |
| Closing Cash & Cash Equivalent | 38 | 68 | 34 | -22 | 16 | 21 | 21 | 112 | 37 | 74 | 79 |
| # | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Earnings Per Share (Rs) | 2.04 | 0.3 | 0.93 | 1.73 | 7.62 | 0.39 | 0.25 | 5.38 | 15.22 | 31.04 | 21.43 |
| CEPS(Rs) | 2.59 | 0.86 | 1.4 | 2.22 | 8.19 | 0.97 | 0.94 | 7.05 | 16.56 | 34.86 | 26.84 |
| DPS(Rs) | 0.35 | 0.1 | 0.15 | 0.3 | 0.4 | 0.1 | 0.1 | 0.2 | 1 | 2 | 1 |
| Book NAV/Share(Rs) | 14.38 | 14.56 | 15.49 | 16.93 | 24.2 | 25.71 | 35.28 | 39.39 | 53.04 | 188.1 | 208.8 |
| Core EBITDA Margin(%) | 25.97 | 7.72 | 18.32 | 18.08 | 41.94 | 13.51 | 6.55 | 33.18 | 41.1 | 39.29 | 35.96 |
| EBIT Margin(%) | 27.8 | 10.02 | 18.29 | 17.34 | 40.24 | 9.98 | 6.93 | 34.64 | 42.84 | 43.7 | 44.63 |
| Pre Tax Margin(%) | 25.1 | 5.53 | 14.53 | 12.12 | 38 | 7.98 | 4.74 | 32.77 | 42.32 | 41.71 | 43.14 |
| PAT Margin (%) | 19.94 | 4.39 | 11.57 | 14.44 | 39.28 | 5.08 | 3.74 | 22.83 | 29.44 | 30.74 | 31.69 |
| Cash Profit Margin (%) | 25.35 | 12.57 | 17.44 | 18.56 | 42.34 | 14.14 | 10.67 | 25.6 | 31.64 | 32.33 | 35.24 |
| ROA(%) | 10.3 | 1.35 | 4.58 | 7.47 | 29.02 | 1.4 | 0.95 | 12.36 | 21.4 | 21.42 | 10.38 |
| ROE(%) | 15.03 | 2.08 | 6.18 | 10.65 | 36.95 | 1.42 | 1.08 | 16.83 | 34.13 | 27.92 | 12.16 |
| ROCE(%) | 16.43 | 3.48 | 7.99 | 10.39 | 32.42 | 2.73 | 1.92 | 24.51 | 48.86 | 38.61 | 16.83 |
| Receivable days | 152.28 | 215.46 | 68.45 | 160.96 | 133.68 | 217.48 | 131.58 | 97.63 | 111.98 | 111.51 | 168.37 |
| Inventory Days | 57.48 | 85.79 | 52.12 | 85.49 | 60.3 | 95.96 | 103.71 | 61.67 | 90.48 | 54.05 | 81.59 |
| Payable days | 39.14 | 64.64 | 77.39 | 78.91 | 61.87 | 160.35 | 99.01 | 33.2 | 60.05 | 28.47 | 82.49 |
| PER(x) | 27.68 | 245.01 | 71.55 | 42.76 | 2.99 | 198.82 | 819.98 | 60.95 | 62.76 | 47.6 | 59.64 |
| Price/Book(x) | 3.92 | 5.05 | 4.29 | 4.36 | 0.94 | 3.03 | 5.8 | 8.32 | 18.01 | 7.85 | 6.12 |
| Dividend Yield(%) | 0.62 | 0.14 | 0.23 | 0.41 | 1.76 | 0.13 | 0.05 | 0.06 | 0.1 | 0.14 | 0.08 |
| EV/Net Sales(x) | 5.57 | 10.27 | 7.95 | 6.49 | 1.02 | 10.62 | 22.34 | 11.16 | 17.89 | 13.34 | 16.27 |
| EV/Core EBITDA(x) | 16.69 | 56.28 | 32.73 | 30.28 | 2.37 | 55.76 | 156.69 | 30.6 | 40.21 | 29.47 | 33.63 |
| Net Sales Growth(%) | 69.46 | -33.02 | 17.18 | 49.57 | 61.88 | -63.4 | 27.66 | 213.75 | 100.99 | 121.36 | -29.37 |
| EBIT Growth(%) | 756.32 | -75.91 | 114.48 | 41 | 275.75 | -90.92 | -11.35 | 1468.2 | 148.59 | 125.78 | -27.86 |
| PAT Growth(%) | 0 | -85.27 | 209.39 | 85.69 | 340.3 | -95.27 | -5.91 | 1814.78 | 159.17 | 131.14 | -27.2 |
| EPS Growth(%) | 0 | -85.27 | 209.39 | 85.7 | 341.31 | -94.86 | -36.19 | 2052.66 | 183.09 | 103.98 | -30.97 |
| Debt/Equity(x) | 0.36 | 0.36 | 0.09 | 0.32 | 0.01 | 0.01 | 0.05 | 0.02 | 0 | 0.03 | 0 |
| Current Ratio(x) | 1.99 | 2.21 | 3.98 | 1.68 | 8.76 | 13.39 | 3.82 | 2.37 | 2.29 | 7.39 | 8.86 |
| Quick Ratio(x) | 1.75 | 1.99 | 3.58 | 1.2 | 7.71 | 11.88 | 3.48 | 2.02 | 1.66 | 6.91 | 7.78 |
| Interest Cover(x) | 10.29 | 2.23 | 4.86 | 3.32 | 17.93 | 5 | 3.16 | 18.6 | 82.6 | 21.96 | 29.82 |
| Total Debt/Mcap(x) | 0.09 | 0.07 | 0.02 | 0.07 | 0.01 | 0 | 0.01 | 0 | 0 | 0 | 0 |
| # | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Promoter | 55.07 | 55.07 | 51.26 | 49.05 | 49.05 | 49.05 | 48.51 | 48.51 | 48.51 | 48.51 |
| FII | 3.84 | 3.08 | 5.72 | 8.27 | 5.93 | 6.03 | 5.95 | 5.55 | 5.99 | 6.46 |
| DII | 3.32 | 3.38 | 8.05 | 9 | 9.49 | 8.76 | 7.93 | 7.85 | 10.06 | 10.41 |
| Public | 37.77 | 38.47 | 34.97 | 33.69 | 35.53 | 36.16 | 37.61 | 38.08 | 35.43 | 34.61 |
| Others | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 |
| # | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Promoter | 4.63 | 4.63 | 4.63 | 4.43 | 4.43 | 4.43 | 4.38 | 4.38 | 4.38 | 4.38 |
| FII | 0.32 | 0.26 | 0.52 | 0.75 | 0.54 | 0.54 | 0.54 | 0.5 | 0.54 | 0.58 |
| DII | 0.28 | 0.28 | 0.73 | 0.81 | 0.86 | 0.79 | 0.72 | 0.71 | 0.91 | 0.94 |
| Public | 3.17 | 3.23 | 3.16 | 3.04 | 3.21 | 3.27 | 3.4 | 3.44 | 3.2 | 3.12 |
| Others | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 8.4 | 8.4 | 9.03 | 9.03 | 9.03 | 9.03 | 9.03 | 9.03 | 9.03 | 9.03 |
| # | 1 Year | 3 Year | 5 Year | 10 Year |
|---|---|---|---|---|
| Sales CAGR | -29% | +46% | +66% | +24% |
| Operating Profit CAGR | -24% | +61% | +102% | +29% |
| PAT CAGR | -27% | +63% | +136% | +30% |
| Share Price CAGR | +11% | +31% | +51% | +36% |
| ROE Average | +12% | +25% | +18% | +15% |
| ROCE Average | +17% | +35% | +26% | +19% |
| # | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Promoter | 55.07 | 55.07 | 51.26 | 49.05 | 49.05 | 49.05 | 48.51 | 48.51 | 48.51 | 48.51 |
| FII | 3.84 | 3.08 | 5.72 | 8.27 | 5.93 | 6.03 | 5.95 | 5.55 | 5.99 | 6.46 |
| DII | 3.32 | 3.38 | 8.05 | 9 | 9.49 | 8.76 | 7.93 | 7.85 | 10.06 | 10.41 |
| Public | 37.77 | 38.47 | 34.97 | 33.69 | 35.53 | 36.16 | 37.61 | 38.08 | 35.43 | 34.61 |
| Others | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 |
| # | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Promoter | 4.63 | 4.63 | 4.63 | 4.43 | 4.43 | 4.43 | 4.38 | 4.38 | 4.38 | 4.38 |
| FII | 0.32 | 0.26 | 0.52 | 0.75 | 0.54 | 0.54 | 0.54 | 0.5 | 0.54 | 0.58 |
| DII | 0.28 | 0.28 | 0.73 | 0.81 | 0.86 | 0.79 | 0.72 | 0.71 | 0.91 | 0.94 |
| Public | 3.17 | 3.23 | 3.16 | 3.04 | 3.21 | 3.27 | 3.4 | 3.44 | 3.2 | 3.12 |
| Others | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 8.4 | 8.4 | 9.03 | 9.03 | 9.03 | 9.03 | 9.03 | 9.03 | 9.03 | 9.03 |
* The pros and cons are machine generated.
Our experts help you choose the right stocks based on performance, risk, and growth potential.
Looking to buy unlisted shares or need guidance on the investment process? Our expert Private Equity Advisors are here to assist you with accurate information, real-time pricing, and seamless execution.
Want to sell unlisted shares, liquidate your ESOPs, or understand the step-by-step process of liquidation? Connect with our Buying Team for smooth coordination, quick evaluations, and end-to-end support.
Planning to build or grow your portfolio? For Mutual Fund investments, PMS solutions, tailored portfolio creation, and overall wealth management, our dedicated Wealth Team is ready to guide you.
Your relationship manager will connect with you shortly.